Gene and cell therapies for central nervous system (CNS) disorders offer promising treatment alternatives for conditions like Parkinson’s disease, Alzheimer’s disease and multiple sclerosis. Gene therapies involve the use of genetically engineered viruses to deliver new genes directly into cells, replacing mutated or missing genes to compensate for the underlying cause of diseases. For neurodegenerative conditions where cell loss is a hallmark pathology, cell therapies utilize various cell types like mesenchymal stem cells, neural stem cells and glial cells with the aim to replace damaged cells and promote tissue regeneration in the brain and spinal cord. These advanced treatment options aim to halt or slow disease progression while bringing long lasting therapeutic benefits.
The global Gene and Cell Therapies Targeting CNS Disorders Market is estimated to be valued at US$ 1.5 billion in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Gene therapy is gaining prominence due to its ability to deliver long term effects with limited administration. Ongoing clinical trials are evaluating gene therapies for conditions like Amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Alzheimer’s disease, Canavan disease, Batten disease, Rett syndrome, Sanfilippo syndrome, and Tay-Sachs disease. In 2020, Novartis received FDA approval for the first ever gene therapy Zolgensma to treat spinal muscular atrophy. Moreover, cell-based therapies utilizing mesenchymal stem cells, neural stem cells, oligodendrocyte progenitor cells and retinal pigment epithelial cells are under extensive research to regenerate cells lost in neurodegenerative disorders. Advanced development of induced pluripotent stem cell (iPSC) technology is also fueling the pipeline of novel cell therapy candidates. Overall, the growing research and development activities in this space are expected to bring new treatment options and drive the market growth over the forecast period.
Threat of new entrants: Low, high capital investments in R&D act as entry barriers for new players.
Bargaining power of buyers: Moderate, presence of alternative therapy options provides bargaining power to buyers.
Bargaining power of suppliers: Moderate, intellectual property rights on technologies gives suppliers an edge.
Threat of new substitutes: Moderate, new therapeutic areas like regenerative medicines can potentially substitute cell and gene therapies.
Competitive rivalry: High, major players compete on innovation, portfolio expansion and market share.
The Global Gene And Cell Therapies Targeting CNS Disorders Market is expected to witness high growth. The global Gene and Cell Therapies Targeting CNS Disorders Market is estimated to be valued at US$ 1.5 billion in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030.
The North America region currently dominates the market and is expected to continue its dominance during the forecast period. This is attributed to growing research funding, rapid development of novel gene and cell therapies, and strategic initiatives by key players in the region.
Key players operating in the Gene and Cell Therapies Targeting CNS Disorders Market are UniQure N.V., BlueRock Therapeutics, Voyager Therapeutics, Spark Therapeutics, Astrocyte, Neuron Therapeutics AG, Anthropic, Bristol-Myers Squibb and Boston Pharmaceuticals.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it